Option chain shows key data for Invictus MD Strategies's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Invictus MD Strategies.

Invictus MD Strategies (OTC:IVITF) Stock, Option Chain

Invictus MD Strategies Corp is a cannabis company with a focus on the Canadian cannabis space, offering a selection of products under a wide range of cannabinoid profiles that fit the demand of the company's medical clients and retail customers. Its wholly-owned subsidiary's Phase I and Phase II facilities are in full production. The company's 50% owned subsidiary has completed its Phase II expansion and received its amended license from Health Canada. Another of its wholly owned subsidiary, connects medical clients to physicians for medical cannabis.

Cannabis

News

Penny Stocks

Small Cap

After-Hours Center

Markets

Movers

Trading Ideas

ARNA

BLOZF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CXXIF

EMERALD HEALTH THERAPUTCS by Emerald Health Therapeutics Inc.

EMHTF

EMPOWER CLINICS INC by Empower Clinics Inc.

EPWCF

GNLN

INLB

ITHUF

IVITF

KSHB

MBII

MGCLF

SNDL

SOLCF

XXII

YCBD

GAINERS:


	Invictus MD Strategies (OTC: IVITF) shares closed up 32.78% at $0.024


Sundial Growers &amp; KushCo Among Top Cannabis Stock Movers On August 9, 2021

Options

BMMJ

CNGGF

CNVCF

CRLBF

CVSI

EAST

HERTF

NDVAF

RHNMF

TGIFF

TLRY

GAINERS:


	Rhinomed (OTC: RHNMF) shares closed up 10.93% at $0.15


Slight Correction For Cannabis Stocks After A Ramping Week, Check Out The Top Movers For July 30, 2021

CRBP

CRON

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

GENE

GRWG

HEXO

HSTRF

MMNFF

GAINERS:


	Tilray (NASDAQ: TLRY) shares closed up 25.77% at $16.01


Bullish Sentiment Pushing Cannabis Stocks Up, Check Out Top Movers For July 28, 2021

INVICTUS MD STRAT NEW by Invictus MD Strategies Corp.

Invictus MD Strategies Corp

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Cardiol Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

CRDL

HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target

Barclays analyst Eddie Kim downgrades Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) from Overweight to Equal-Weight and lowers the price target from $59 to $49.

Downgrades

Barclays Downgrades Valaris to Equal-Weight, Lowers Price Target to $49

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and raises the price target from $11 to $19.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Raises Price Target to $19

BTCM

BIT Mining Receives NYSE Letter That It Regained Compliance With Quantitative Continued Listing Standards

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

Barclays analyst David Anderson downgrades Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Overweight to Equal-Weight and lowers the price target from $43 to $33.

Barclays Downgrades Halliburton to Equal-Weight, Lowers Price Target to $33

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones

Needham analyst Laura Martin reiterates Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) with a Buy and maintains $5 price target.

TBLA

Needham Reiterates Buy on Taboola.com, Maintains $5 Price Target

JP Morgan analyst Cory Carpenter maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Overweight and raises the price target from $195 to $225.

TTWO

JP Morgan Maintains Overweight on Take-Two Interactive, Raises Price Target to $225

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $21 price target.

PDSB

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

JP Morgan analyst David Karnovsky downgrades PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) from Neutral to Underweight.

MYPS

JP Morgan Downgrades PLAYSTUDIOS to Underweight

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $375 price target.

Needham Reiterates Buy on Salesforce, Maintains $375 Price Target

JP Morgan analyst Doug Anmuth downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Overweight to Neutral.

ANGI

JP Morgan Downgrades Angi to Neutral

UMC will purchase more than 30 billion kilowatt-hours of power from Fengmiao I over least 30 years.
&nbsp;This agreement will help UMC achieve its goal of 50% renewable energy use by 2030 as part of the company's roadmap to net zero emissions and 100% renewable energy by 2050.

United Microelectronics Inks 30-Year, 30B kWh Offshore Wind Power Agreement  With Fengmiao I

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Buy and maintains $25 price target.

ALXO

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target

JP Morgan analyst Cory Carpenter downgrades Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) from Neutral to Underweight.

GETY

JP Morgan Downgrades Getty Images Holdings to Underweight

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts

PLRZ

Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025

CMPS

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index

JP Morgan analyst Cory Carpenter upgrades Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) from Neutral to Overweight and raises the price target from $25 to $45.

Upgrades

XMTR

JP Morgan Upgrades Xometry to Overweight, Raises Price Target to $45

JP Morgan analyst Cory Carpenter downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Overweight to Neutral and lowers the price target from $40 to $33.

Comments

Invictus MD Strategies

Invictus MD Strategies (IVITF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga